ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Hodgkin Lymphoma in Houston, TX

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Cancer

Non-Hodgkin Lymphoma trials near Houston, TX, USA:

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a po-...

Enrolling
Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)
Drug: ARV-393

Phase 1

Arvinas
Arvinas

Houston, Texas, United States and 7 other locations

radiotherapy in participants with relapsed or refractory non-Hodgkin's lymphoma (NHL). Two dose levels of SIRPant-M are be...

Enrolling
Relapsed Non-Hodgkin Lymphoma
Refractory Non-Hodgkin Lymphoma
Radiation: External-beam radiotherapy (XRT)
Biological: SIRPant-M

Phase 1

SIRPant Immunotherapeutics

Houston, Texas, United States and 2 other locations

The purpose of this Phase 1 study is to evaluate the safety and tolerability of CC-96673 in adult participants with Relapsed or Refractory Non...

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: CC-96673

Phase 1

Celgene
Celgene

Houston, Texas, United States and 12 other locations

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...

Enrolling
Lymphoma, Non-Hodgkin
Drug: Obinutuzumab
Drug: CC-99282

Phase 1, Phase 2

Celgene
Celgene

Houston, Texas, United States and 89 other locations

This is a Phase 1/2 study of imvotamab in adult subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma. This stu...

Active, not recruiting
Marginal Zone Lymphoma
Mantle Cell Lymphoma
Drug: imvotamab

Phase 1, Phase 2

IGM Biosciences

Houston, Texas, United States and 26 other locations

to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy
Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)

Phase 3

Novartis
Novartis

Houston, Texas, United States and 66 other locations

CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non...

Enrolling
Refractory B-Cell Non-Hodgkin Lymphoma
B Cell Lymphoma
Genetic: CB-010
Drug: Cyclophosphamide

Phase 1

Caribou Biosciences

Houston, Texas, United States and 29 other locations

Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL.Part 2: To characterize th...

Active, not recruiting
Non Hodgkin Lymphoma
Drug: acalabrutinib
Drug: rituximab (IV)

Phase 1, Phase 2

Acerta Pharma
Acerta Pharma

Houston, Texas, United States and 31 other locations

in participants with relapsed or refractory (R/R) CD30-expressing lymphomas.GEN3017 will be administered via subcutaneous injections.All par...

Enrolling
Classical Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Biological: GEN3017

Phase 1, Phase 2

Genmab
Genmab

Houston, Texas, United States and 5 other locations

tolerability of CHO-H01 in subjects with relapsed/refractory CD20+ non-Hodgkin's lymphoma. It will also determine maximum ...

Enrolling
Non-Hodgkin Lymphoma
Biological: CHO-H01

Phase 1, Phase 2

Cho Pharma

The Woodlands, Texas, United States and 7 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems